Yield10 Bioscience R&D per Employee
The R&D Spending per Employee of Yield10 Bioscience (YTENQ) as of Sep 17, 2026 is 277,433.33 USD. In the previous year, R&D Spending per Employee was 258,333.33 USD — a change of 7.39% (higher).
Get this data via API
Financial Data API
R&D per Employee
277,433.33USD
YoY
7.39%
Last updated:
The Yield10 Bioscience R&D per Employee history
3 Years
10 Years
25 Years
Max
| YEAR | R&D per Employee | YoY |
|---|---|---|
| 277,433.33USD | +7.39% | |
| 258,333.33USD | +27.89% | |
| 202,000.00USD | +13.06% | |
| 178,666.67USD | +10.52% | |
| 161,666.67USD | +1.46% | |
| 159,333.33USD | +3.91% | |
| 153,333.33USD | -18.87% | |
| 189,000.00USD | -14.09% | |
| 220,000.00USD | -61.94% | |
| 578,000.00USD | — |
Yield10 Bioscience Stock analysis
Frequently Asked Questions about Yield10 Bioscience stock
R&D Spending per Employee of Yield10 Bioscience is 277,433.33 USD in 2026.
R&D Spending per Employee of Yield10 Bioscience changed from 258,333.33 USD to 277,433.33 USD, representing a 7.39% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of R&D Spending per Employee Yield10 Bioscience since 2006 – with annual values, charts, and detailed analysis.
R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.
R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Yield10 Bioscience historically and in real time.
Workforce — Yield10 Bioscience
All Key Metrics — Yield10 Bioscience
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth